We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
TEVIMBRA BeOne Medicines AUS Pty Ltd
Product name
TEVIMBRA
Sponsor
Accepted date
Apr-2026
Active ingredients
tislelizumab
Summary of proposed indication
TEVIMBRA (tislelizumab), in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of adult patients with resectable NSCLC at high risk of recurrence.
Application type
C (new indication)
Publication date
Apr-2026